Santen combination treatment reduces IOP in VISIONARY study

Patients treated with topical preservative-free tafluprost and timolol fixed-dose combination experienced a statistically and clinically significant IOP reduction, according to preliminary results of Santen’s real-world evidence VISIONARY study at the European Society of Ophthalmology congress.
The recently completed noninterventional European prospective study evaluated the effectiveness, tolerability and safety of topical preservative-free tafluprost 0.0015% and timolol 0.5% fixed-dose combination treatment in adults with open-angle glaucoma and ocular hypertension, according to a

Full Story →